The COVID-19 pandemic demonstrated that the biopharmaceutical manufacturing industry can continue to benefit from more advances to help improve and accelerate vaccine manufacturing processes to bolster the nation’s pandemic response capability.
MIT will demonstrate the rapid production of virus-like particle (VLP) vaccine candidates manufactured using a transposon-based system. This process involves co-transfection to yield polyclonal cell lines that secrete self-assembling SARS-CoV-2 VLPs containing the four viral structural proteins.
The team’s expertise in synthetic biology, biological process modeling and control, machine learning, and manufacturing process development can help shorten timelines for process development and scale-up.
The MIT team aims to improve product development of VLPs, mechanistic modeling for rapid-cycle process development and improved process control.
By demonstrating this transposon-based system, the team will provide industry with tools and approaches to rapidly develop and manufacture effective virus-like particle vaccines, adding robustness to the nation’s pandemic response to emerging viruses.
Login to the NIIMBL member portal to access more, including:
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.
Massachusetts Institute of Technology
